<DOC>
	<DOC>NCT03005678</DOC>
	<brief_summary>A randomized controlled trial to compare for the efficacy and tolerability of denosumab and oral alendronate in the management of glucocorticoid induced osteoporosis</brief_summary>
	<brief_title>Denosumab Versus Bisphosphonates (Alendronate) in GIOP</brief_title>
	<detailed_description>Study design: an open-label randomized controlled trial Duration of study: 12 months Treatment arms: 1. Denosumab: a total of 2 doses in a period of 12 months 2. Oral alendronate: weekly dose in a period of 12 months Target sample size: 220 patients (110 patients in each arm)</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>1. Adults (women or men) &gt;18 years of age 2. Receiving longterm prednisolone treatment for various medical illnesses, defined as a daily prednisolone dose of ≥2.5mg/day for ≥12 months). 3. Informed consent from patients. 4. Willing to comply with all study procedures 1. Patients with previous use of denosumab, teriparatide, intravenous bisphosphonates, strontium or other experimental antiosteoporotic agents. 2. Premenopausal women who plan for pregnancy within 18 months of study entry. 3. Patients with known bone disorders such as osteomalacia, renal osteodystrophy, and hyperparathyroidism. 4. Patients with unexplained hypocalcemia. 5. Patients with serum creatinine level of &gt;=200umol/L.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>glucocorticoids, steroids, osteoporosis</keyword>
</DOC>